Gemini Smith
5 posts
Sep 23, 2024
9:35 PM
|
T cell Ig and ITIM domain (TIGIT) is expressed on the surface of natural killer (NK) cells, regulatory T cells (Tregs), and T cells, among other lymphoid cells. Numerous investigations have revealed that TIGIT identifies the most dysfunctional subgroup of Tregs and CD8+ T cells, exhibiting a highly suppressive behavior in many scenarios. Furthermore, TIGIT blocking has therapeutic advantages in various animal tumor types.
Only monoclonal antibodies that bind to TIGIT specifically will be designed by this program. We know that when combined with anti-PD1, anti-TIGIT exhibits superior anti-tumor activity. For further help with combination medicines, please contact our scientists.
For more: cancer immunotherapies targeting TIGIT
|
